Literature DB >> 29739853

Mycobacterium tuberculosis PPE60 antigen drives Th1/Th17 responses via Toll-like receptor 2-dependent maturation of dendritic cells.

Haibo Su1,2, Zhen Zhang2, Zijian Liu1, Baozhou Peng1, Cong Kong3, Honghai Wang3, Zhi Zhang4, Ying Xu5.   

Abstract

Targeting of Mycobacterium tuberculosis (MTB) PE/PPE antigens that induce type 1 helper T cell (Th1) and Th17 responses represents a crucial strategy for the development of tuberculosis (TB) vaccines. However, only a few PE/PPE antigens induce these responses. Here, we sought to determine how the cell wall-associated antigen PPE60 (Rv3478) activates dendritic cell (DC) maturation and T-cell differentiation. We observed that PPE60 induces DC maturation by augmenting the protein expression of cluster of differentiation 80 (CD80) and CD86 and major histocompatibility complex (MHC) class I and MHC class II on the cell surface. PPE60 also stimulated the production of tumor necrosis factor-α (TNFα), interleukin (IL)-1β, IL-6, IL-12p70, and IL-23p19 but not IL-10. This induction was mediated by Toll-like receptor 2 (TLR2) and followed by activation of p38, c-Jun N-terminal kinase (JNK), and NF-κB signaling. PPE60 enhanced MHC-II expression and promoted antigen processing by DCs in a TLR2-dependent manner. Moreover, PPE60-stimulated DCs directed naïve CD4+ T cells to produce IFN-γ, IL-2, and IL-17A, expanding the Th1 and Th17 responses, along with activation of T-bet and RAR-related orphan receptor C (RORγt) but not GATA-3. Moreover, PPE60 activated the NLRP3 inflammasome followed by caspase-1-dependent IL-1β and IL-18 synthesis in DCs. Of note, pharmacological inhibition of NLRP3 activation specifically attenuated IFN-γ and IL-17A secretion into the supernatant from CD4+ T cells cocultured with PPE60-activated DCs. These findings indicate that PPE60 induces Th1 and Th17 immune responses by activating DCs in a TLR2-dependent manner, suggesting PPE60's potential for use in MTB vaccine development.
© 2018 Su et al.

Entities:  

Keywords:  CD4+ T cell; Mycobacterium tuberculosis; PE/PPE proteins; TLR; Toll-like receptor; antigen processing; dendritic cell; helper T cell response; tuberculosis; tuberculosis vaccine

Mesh:

Substances:

Year:  2018        PMID: 29739853      PMCID: PMC6028961          DOI: 10.1074/jbc.RA118.001696

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

Review 1.  The success and failure of BCG - implications for a novel tuberculosis vaccine.

Authors:  Peter Andersen; T Mark Doherty
Journal:  Nat Rev Microbiol       Date:  2005-08       Impact factor: 60.633

2.  NLRP3 inflammasome activation by mycobacterial ESAT-6 and dsRNA in intraocular tuberculosis.

Authors:  Soumyava Basu; Benjamin J Fowler; Nagaraj Kerur; Kristine B Arnvig; Narsing A Rao
Journal:  Microb Pathog       Date:  2017-11-24       Impact factor: 3.738

3.  Mycobacterium tuberculosis protein ESAT-6 is a potent activator of the NLRP3/ASC inflammasome.

Authors:  Bibhuti B Mishra; Pedro Moura-Alves; Avinash Sonawane; Nir Hacohen; Gareth Griffiths; Luis F Moita; Elsa Anes
Journal:  Cell Microbiol       Date:  2010-02-09       Impact factor: 3.715

4.  Src homology 3-interacting domain of Rv1917c of Mycobacterium tuberculosis induces selective maturation of human dendritic cells by regulating PI3K-MAPK-NF-kappaB signaling and drives Th2 immune responses.

Authors:  Kushagra Bansal; Akhauri Yash Sinha; Devram Sampat Ghorpade; Shambhuprasad Kotresh Togarsimalemath; Shripad A Patil; Srini V Kaveri; Kithiganahalli Narayanaswamy Balaji; Jagadeesh Bayry
Journal:  J Biol Chem       Date:  2010-09-13       Impact factor: 5.157

5.  Execution of macrophage apoptosis by PE_PGRS33 of Mycobacterium tuberculosis is mediated by Toll-like receptor 2-dependent release of tumor necrosis factor-alpha.

Authors:  Sanchita Basu; Sushil Kumar Pathak; Anirban Banerjee; Shresh Pathak; Asima Bhattacharyya; Zhenhua Yang; Sarah Talarico; Manikuntala Kundu; Joyoti Basu
Journal:  J Biol Chem       Date:  2006-11-09       Impact factor: 5.157

6.  Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved.

Authors:  Iñaki Comas; Jaidip Chakravartti; Peter M Small; James Galagan; Stefan Niemann; Kristin Kremer; Joel D Ernst; Sebastien Gagneux
Journal:  Nat Genet       Date:  2010-05-23       Impact factor: 38.330

7.  Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis.

Authors:  Andrea Cruz; Alexandra G Fraga; Jeffrey J Fountain; Javier Rangel-Moreno; Egídio Torrado; Margarida Saraiva; Daniela R Pereira; Troy D Randall; Jorge Pedrosa; Andrea M Cooper; António G Castro
Journal:  J Exp Med       Date:  2010-07-12       Impact factor: 14.307

8.  The PPE18 of Mycobacterium tuberculosis interacts with TLR2 and activates IL-10 induction in macrophage.

Authors:  Shiny Nair; Poongothai A Ramaswamy; Sudip Ghosh; Dhananjay C Joshi; Niteen Pathak; Imran Siddiqui; Pawan Sharma; Seyed E Hasnain; Shekhar C Mande; Sangita Mukhopadhyay
Journal:  J Immunol       Date:  2009-10-30       Impact factor: 5.422

9.  Genetic requirements for mycobacterial survival during infection.

Authors:  Christopher M Sassetti; Eric J Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

10.  PPE26 induces TLR2-dependent activation of macrophages and drives Th1-type T-cell immunity by triggering the cross-talk of multiple pathways involved in the host response.

Authors:  Haibo Su; Cong Kong; Lin Zhu; Qi Huang; Liulin Luo; Honghai Wang; Ying Xu
Journal:  Oncotarget       Date:  2015-11-17
View more
  8 in total

1.  MiR-25 blunts autophagy and promotes the survival of Mycobacterium tuberculosis by regulating NPC1.

Authors:  Wenqi Dong; Gaoyan Wang; Jiajia Feng; Pei Li; Rui Wang; Hao Lu; Wenjia Lu; Chenchen Wang; Xiangru Wang; Huanchun Chen; Yaozu Xiang; Chen Tan
Journal:  iScience       Date:  2022-04-22

2.  Suppression of Th1 Priming by TLR2 Agonists during Cutaneous Immunization Is Mediated by Recruited CCR2+ Monocytes.

Authors:  Christopher T Johndrow; Michael F Goldberg; Alison J Johnson; Tony W Ng; Shajo Kunnath-Velayudhan; Gregoire Lauvau; Daniel H Kaplan; Graeme H Gossel; Ulrich D Kadolsky; Andrew J Yates; John Chan; William R Jacobs; Steven A Porcelli
Journal:  J Immunol       Date:  2018-11-19       Impact factor: 5.422

3.  In-host population dynamics of Mycobacterium tuberculosis complex during active disease.

Authors:  Roger Vargas; Luca Freschi; Maximillian Marin; L Elaine Epperson; Melissa Smith; Irina Oussenko; David Durbin; Michael Strong; Max Salfinger; Maha Reda Farhat
Journal:  Elife       Date:  2021-02-01       Impact factor: 8.140

Review 4.  Role of the PE/PPE Family in Host-Pathogen Interactions and Prospects for Anti-Tuberculosis Vaccine and Diagnostic Tool Design.

Authors:  Jianing Qian; Run Chen; Honghai Wang; Xuelian Zhang
Journal:  Front Cell Infect Microbiol       Date:  2020-11-26       Impact factor: 5.293

Review 5.  The Mycobacterium tuberculosis PE_PGRS Protein Family Acts as an Immunological Decoy to Subvert Host Immune Response.

Authors:  Tarina Sharma; Anwar Alam; Aquib Ehtram; Anshu Rani; Sonam Grover; Nasreen Z Ehtesham; Seyed E Hasnain
Journal:  Int J Mol Sci       Date:  2022-01-04       Impact factor: 5.923

Review 6.  Pathological and protective roles of dendritic cells in Mycobacterium tuberculosis infection: Interaction between host immune responses and pathogen evasion.

Authors:  Hongmin Kim; Sung Jae Shin
Journal:  Front Cell Infect Microbiol       Date:  2022-07-28       Impact factor: 6.073

7.  Mycobacterium avium subsp. paratuberculosis MAP1889c Protein Induces Maturation of Dendritic Cells and Drives Th2-biased Immune Responses.

Authors:  Hye-Soo Park; Yong Woo Back; Yeo-Jin Son; Hwa-Jung Kim
Journal:  Cells       Date:  2020-04-11       Impact factor: 6.600

Review 8.  What Do In Vitro and In Vivo Models Tell Us about Anisakiasis? New Tools Still to Be Explored.

Authors:  Serena Cavallero; Ilaria Bellini; Antonella Pizzarelli; Stefano D'Amelio
Journal:  Pathogens       Date:  2022-02-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.